Jenscare Scientific Co., Ltd. announced that on October 11, 2023, the Company received a confirmation letter from the National Medical Products Administration of the People's Republic of China (Guo Jia Yao Pin Jian Du Guan Li Ju) (" NMPA"), confirming the acceptance of the registration application for Ken-Valve. Ken-Valve is the first-generation transcatheter aortic heart valve implantation system independently developed by the Company, designed to meet the needs of patients with severe aortic regurgitation (or combined with aortic stenosis). There is no assurance that the Company will ultimately develop, market and/or commercialize Ken-Valve successfully.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.